Literature DB >> 22271461

Conformational comparability of factor IX-Fc fusion protein, factor IX, and purified Fc fragment in the absence and presence of calcium.

Damian Houde1, Steven A Berkowitz.   

Abstract

A long lasting recombinant factor IX -Fc fusion protein (rFIX-Fc) is being developed for the treatment of hemophilia B and is currently in late stage clinical investigation. By limiting injection frequency and maintaining efficacy, rFIX-Fc shows promise as a new therapeutic option for hemophilia B patients. However, before gaining regulatory approval, rFIX-Fc must undergo rigorous analytical and biological testing, in addition to clinical trials. Included in this testing is the need to understand this protein's higher-order structure and dynamics. In this study, we investigated and compared the biophysical properties of rFIX-Fc, rFIX, and Fc using hydrogen/deuterium exchange mass spectrometry and differential scanning calorimetry. Within the limits of these techniques, our results show that structural comparability exists between rFIX and the FIX region of rFIX-Fc. In addition, changes in the structure and dynamics of both proteins, in response to calcium binding, a requirement for FIX function, are also highly comparable. In the case of Fc and Fc region of rFIX-Fc, conformational comparability is also established. These biophysical results further support the conclusion that fusing an immunoglobulin gamma 1 Fc to rFIX does not significantly alter the higher-order structure of FIX or Fc, Ca binding to FIX, or Fc functionality.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271461     DOI: 10.1002/jps.23064

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  A gene-specific method for predicting hemophilia-causing point mutations.

Authors:  Nobuko Hamasaki-Katagiri; Raheleh Salari; Andrew Wu; Yini Qi; Tal Schiller; Amanda C Filiberto; Enrique F Schisterman; Anton A Komar; Teresa M Przytycka; Chava Kimchi-Sarfaty
Journal:  J Mol Biol       Date:  2013-08-03       Impact factor: 5.469

Review 2.  Advances in Hydrogen/Deuterium Exchange Mass Spectrometry and the Pursuit of Challenging Biological Systems.

Authors:  Ellie I James; Taylor A Murphree; Clint Vorauer; John R Engen; Miklos Guttman
Journal:  Chem Rev       Date:  2021-09-07       Impact factor: 72.087

Review 3.  Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications.

Authors:  Hui Wei; Jingjie Mo; Li Tao; Reb J Russell; Adrienne A Tymiak; Guodong Chen; Roxana E Iacob; John R Engen
Journal:  Drug Discov Today       Date:  2013-08-06       Impact factor: 7.851

4.  Biophysical characterization and structure of the Fab fragment from the NIST reference antibody, RM 8671.

Authors:  Ioannis Karageorgos; Elyssia S Gallagher; Connor Galvin; D Travis Gallagher; Jeffrey W Hudgens
Journal:  Biologicals       Date:  2017-09-29       Impact factor: 1.856

Review 5.  Applications of hydrogen/deuterium exchange MS from 2012 to 2014.

Authors:  Gregory F Pirrone; Roxana E Iacob; John R Engen
Journal:  Anal Chem       Date:  2014-11-14       Impact factor: 6.986

6.  The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein.

Authors:  Takuo Suzuki; Noritaka Hashii; Minoru Tada; Akiko Ishii-Watabe
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.